Glioblastoma, the most common malignant brain tumor, is among the deadliest cancers, with most patients facing extremely short survival timelines. A Houston patient diagnosed in late 2024 is defying expectations after undergoing an experimental, personalized cell therapy at UT Health. Early trial results show promise, with about 88% of participants still alive after one year, offering new hope for future GBM treatment.
